HsCRP & Chronic Inflammation: The Longevity Biomarker Your Doctor Ignores

Why Inflammation Is the Master Driver of Aging

In 2000, Claudio Franceschi coined the term "inflammaging" — chronic, low-grade, systemic inflammation that increases with age in the absence of any obvious infection. Two and a half decades later, it's one of the most validated concepts in geroscience. Inflammaging isn't a consequence of aging. It's a cause of it.

The mechanism works like this: as you age, senescent cells accumulate. These zombie cells stop dividing but refuse to die, and they adopt what's called a senescence-associated secretory phenotype (SASP). They pump out pro-inflammatory cytokines — IL-6, TNF-α, IL-1β — 24/7. Your mitochondria start leaking reactive oxygen species (ROS) and mitochondrial DNA fragments that trip the NLRP3 inflammasome. Your gut barrier weakens, letting bacterial lipopolysaccharides (LPS) into circulation. Your macrophages reprogramm toward a pro-inflammatory default.

The result is a body marinating in low-level inflammation that never resolves. Not enough to make you feel sick. More than enough to accelerate atherosclerosis, neurodegeneration, insulin resistance, sarcopenia, and every other hallmark of aging.

This isn't theoretical. A 2024 systematic review and meta-analysis in Frontiers in Immunology confirmed that IL-6, TNF-α, and IL-1β levels track directly with age-related disease incidence. Plasma IL-6 roughly doubles from young adulthood (~1.5 pg/mL) to age 60+ (~3.5 pg/mL). The CANTOS trial — 10,061 patients, randomized, placebo-controlled — proved the concept pharmacologically: targeting IL-1β with canakinumab reduced major cardiovascular events by 15% at the 150mg dose, with a 37% reduction in hsCRP. The drug was too dangerous for broad use (higher fatal infection rates), but the science was bulletproof: reduce inflammation, reduce cardiovascular events.

What HsCRP Actually Measures — and What It Misses

C-reactive protein is an acute-phase reactant produced by the liver in response to IL-6 signaling. The "hs" in hsCRP stands for "high-sensitivity" — it's the same protein, just measured with an assay sensitive enough to detect the low levels that matter for chronic disease risk rather than acute infection.

What makes hsCRP useful is its integration. It doesn't measure one pathway — it reflects the aggregate inflammatory burden from every source: visceral fat, leaky gut, senescent cells, periodontal disease, chronic infections, sleep deprivation. It's downstream of virtually all inflammatory drivers, which makes it a broad-spectrum smoke detector.

What makes it limited is the same thing. HsCRP doesn't tell you where the fire is. An hsCRP of 2.4 mg/L could mean visceral adiposity, a subclinical dental infection, or autoimmune activity. It also spikes transiently from acute illness, injury, or intense exercise — a single reading can mislead. That's why the protocol is always two draws, at least two weeks apart, with no acute illness in between.

The Numbers: Standard Ranges vs. Longevity Targets

The American Heart Association established the standard risk categories in 2003. They haven't updated them in over two decades. Meanwhile, longevity medicine has moved the goalposts — dramatically.

The ACC's 2025 Scientific Statement now recommends universal hsCRP screening in both primary and secondary prevention. That's a massive shift. The statement also explicitly notes that in patients with established cardiovascular disease, elevated hsCRP is a better predictor of future events and death than LDL-C. Read that again. Better than LDL-C.

For longevity optimization, the evidence points to below 0.5 mg/L as the real target. The JUPITER trial showed that patients who achieved hsCRP below 1.0 mg/L on statin therapy had significantly fewer events than those who didn't — regardless of LDL levels. Pair that with the data showing hsCRP predicts major adverse cardiovascular events over 20–30 years of follow-up, and the case for aggressive optimization is overwhelming.

The Full Inflammaging Panel: Beyond HsCRP

HsCRP alone is a smoke detector. A full inflammaging panel is a fire map. If you're serious about longevity, you want the complete picture — especially since some inflammatory drivers don't move hsCRP at all.

GlycA deserves special attention. It's a composite NMR biomarker that measures the glycosylation of five acute-phase proteins simultaneously. Unlike hsCRP, it doesn't spike from a single workout or a cold — it reflects 2–3 weeks of cumulative inflammatory signaling. A 2018 PREVEND study found that higher plasma GlycA was independently associated with reduced life expectancy. If your lab offers NMR lipid panels (most do now through LabCorp or Quest), GlycA is often included.

What Drives Chronic Inflammation — The Source Checklist

Before you start throwing supplements at your hsCRP, find the fire. This is the hierarchy of inflammatory drivers, ranked by impact:

1. Visceral Adiposity — The #1 Driver

Visceral fat isn't inert storage. It's an endocrine organ that secretes IL-6, TNF-α, and leptin while suppressing anti-inflammatory adiponectin. Every kilogram of visceral fat you carry is an active source of systemic inflammation. The data is unambiguous: weight loss reduces hsCRP by approximately 0.25 mg/L for every 6.4 kg lost. If your waist circumference is above 94 cm (men) or 80 cm (women), this is the first and most impactful thing to fix.

2. Metabolic Dysfunction

Insulin resistance and chronic hyperglycemia are both inflammatory. Elevated fasting insulin drives NF-κB activation. High glucose generates advanced glycation end-products (AGEs) that trigger RAGE receptor signaling. If your fasting insulin is above 5 μIU/mL or your HbA1c is above 5.2%, your metabolic health is directly contributing to your inflammatory load. Protocols like metformin or berberine address both the glucose dysregulation and downstream inflammation simultaneously.

3. Gut Permeability

Age-related gut dysbiosis increases intestinal permeability — "leaky gut" in common parlance, LPS translocation in clinical terms. Bacterial lipopolysaccharides crossing the gut barrier persistently activate toll-like receptors, driving chronic NF-κB signaling. If you have bloating, food sensitivities, or unexplained hsCRP elevation without other obvious sources, gut health should be high on the investigation list.

4. Sleep Deprivation

One week of sleeping 4–5 hours per night increases IL-6 by roughly 50% and hsCRP by up to 200% in healthy adults. Sleep is not optional for inflammation management. Seven to nine hours, consistent timing, and actual sleep quality (not just time in bed) are non-negotiable.

5. Chronic Infections & Dental Health

Periodontal disease is one of the most overlooked inflammatory drivers. Chronic gum infection maintains a steady-state of IL-1β, IL-6, and TNF-α production. Other culprits include chronic viral reactivation (EBV, CMV), undiagnosed H. pylori, and fungal overgrowth. If your hsCRP stays stubbornly elevated despite optimizing everything else, look here.

6. Psychological Stress

Chronic stress activates the NLRP3 inflammasome through ATP/P2X7 receptor pathways, elevating IL-1β and IL-6. This isn't "woo." The molecular pathways are well-characterized. HPA axis dysregulation from chronic stress directly feeds the inflammaging loop.

The Anti-Inflammation Protocol: What Actually Works

The interventions below are ranked by effect size — largest documented hsCRP reductions first. This isn't a choose-your-own-adventure. If you're above 1.0 mg/L, stack them in order.

Pharmacological Options: When Lifestyle Isn't Enough

If you've stacked Tiers 1–4 for 8–12 weeks, retested, and your hsCRP is still above 1.0 mg/L, it's time for a conversation with your physician about pharmacological intervention.

Statins — The Residual Inflammatory Risk Angle

Statins reduce hsCRP independently of their LDL-lowering effect. The JUPITER trial proved this: rosuvastatin 20mg reduced hsCRP by 37% in patients with normal LDL but elevated hsCRP, cutting cardiovascular events significantly. If your ApoB is elevated alongside hsCRP, a statin addresses both problems simultaneously.

Low-Dose Colchicine

Originally a gout drug, low-dose colchicine (0.5 mg/day) has an FDA-approved indication for secondary cardiovascular prevention as of 2023. It works by inhibiting the NLRP3 inflammasome and neutrophil-mediated inflammation. The ACC gives it a Class 2b recommendation. If your hsCRP remains elevated despite statin therapy, this is the next conversation to have.

GLP-1 Receptor Agonists

Semaglutide doesn't just cause weight loss. The SELECT trial showed a 20% reduction in major adverse cardiovascular events and a 43.5% reduction in inflammatory markers in heart failure patients with preserved ejection fraction and obesity. If you have both metabolic dysfunction and elevated inflammation, GLP-1 agonists may be killing two birds with one stone.

Rapamycin

Low-dose rapamycin acts on the mTOR pathway, which directly regulates SASP output from senescent cells. By inhibiting mTOR, rapamycin reduces the inflammatory secretion of zombie cells — addressing inflammaging at the source rather than downstream. This is still off-label for longevity, but the mechanistic logic is compelling.

Testing Protocol: How to Track Inflammation Properly

Sex Differences in Inflammaging

This matters and almost nobody talks about it. A 2025 review in Frontiers in Immunology documented clear sex-dependent patterns:

• Men show earlier innate immune activation, beginning around ages 62–64, with higher pro-inflammatory monocyte counts and steeper naïve T-cell decline.
• Women maintain stronger adaptive immunity into older age, with comparable inflammatory changes occurring 4–7 years later. However, post-menopausal estrogen decline accelerates senescence markers and inflammatory burden.
• Estrogen is directly anti-inflammatory: it suppresses mitochondrial ROS, prevents DNA damage-induced senescence through p21 downregulation, and promotes telomerase expression. Post-menopausal women who don't address the estrogen question are fighting inflammaging with one hand tied behind their back.

For women: if your hsCRP jumps during perimenopause or post-menopause, the inflammatory change may be partly hormonal, not lifestyle. Have the hormone conversation alongside the inflammation conversation.

The CANTOS Lesson: Proof That Inflammation Causes Disease

The CANTOS trial deserves its own section because it changed the entire field. Before CANTOS, skeptics could argue that inflammation was merely a marker of cardiovascular disease, not a cause. CANTOS killed that argument.

10,061 patients with previous heart attacks and hsCRP ≥ 2 mg/L were randomized to receive canakinumab (an IL-1β monoclonal antibody) or placebo. The 150mg dose reduced hsCRP by 37% and cardiovascular events by 15%. Critically, this happened without any change in LDL cholesterol. The anti-inflammatory effect alone drove the cardiovascular benefit.

The drug also showed a surprising secondary finding: a dose-dependent reduction in lung cancer incidence and mortality. Inflammation wasn't just driving heart disease — it was feeding cancer.

Canakinumab never became a mainstream treatment because it also increased fatal infections (0.31 vs. 0.18 per 100 person-years vs. placebo). But the scientific proof of concept was locked in: inflammation is causal, not just correlative, in cardiovascular disease and likely in cancer. Every lifestyle and supplement intervention that lowers your hsCRP is operating on the same axis that canakinumab proved matters.

Putting It All Together: The Action Plan